Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase 1 study

被引：0
|
作者：
Berzofsky, Jay [1 ]
Wood, Lauren [1 ]
Maeng, Hoyoung [1 ]
Trepel, Jane [1 ]
Stroncek, David [2 ]
Morris, John [3 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Bethesda, MD 20892 USA
[3] Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2019年 / 81卷
关键词：
D O I：
10.1097/01.qai.0000557959.74614.41
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
C-105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [21] Multicenter phase II trial of trastuzumab and capecitabine in patients with HER2 expressing metastasized pancreatic cancer
    Harder, J.
    Hofheinz, R.
    Moehler, M.
    Buechler, P.
    Kloeppel, G.
    Bitzer, M.
    Endlicher, E.
    Reinacher-Schick, A.
    Heinemann, V.
    Geissler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 389 - 389
  • [22] HER2 Staining Intensity Shows Prognostic Impact on Patients with HER2-Positive Invasive Breast Cancer
    Chen, Yen-Ying
    Hsu, Chih-yi
    MODERN PATHOLOGY, 2018, 31 : 53 - 54
  • [23] HER2 Staining Intensity Shows Prognostic Impact on Patients with HER2-Positive Invasive Breast Cancer
    Chen, Yen-Ying
    Hsu, Chih-Yi
    LABORATORY INVESTIGATION, 2018, 98 : 53 - 54
  • [24] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
    McAndrew, Nicholas P.
    Hu, Xichun
    Zhang, Jian
    Wang, Xiaojia
    Yu, Wenlei
    Pan, Xiaomei
    CANCER RESEARCH, 2023, 83 (05)
  • [25] Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
    J Harder
    G Ihorst
    V Heinemann
    R Hofheinz
    M Moehler
    P Buechler
    G Kloeppel
    C Röcken
    M Bitzer
    S Boeck
    E Endlicher
    A Reinacher-Schick
    C Schmoor
    M Geissler
    British Journal of Cancer, 2012, 106 : 1033 - 1038
  • [26] Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
    Harder, J.
    Ihorst, G.
    Heinemann, V.
    Hofheinz, R.
    Moehler, M.
    Buechler, P.
    Kloeppel, G.
    Roecken, C.
    Bitzer, M.
    Boeck, S.
    Endlicher, E.
    Reinacher-Schick, A.
    Schmoor, C.
    Geissler, M.
    BRITISH JOURNAL OF CANCER, 2012, 106 (06) : 1033 - 1038
  • [27] Early results of a phase I clinical trial of an Ii-Key/HER2/neu MHC Class II peptide-based vaccine in breast cancer patients
    Khoo, Steven
    Storrer, Catherine
    Harris, Katie
    Jama, Yusuf
    Smith, Anna
    Dehqanzada, Zia
    Murray, James
    Shriver, Craig
    von Hofe, Eric
    Ponniah, Sathibalan
    Peoples, George
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 203 (03) : S81 - S81
  • [28] Results of a phase I clinical trial of an Ii-Key/HER2/neu MHC class II peptide-based vaccine in breast cancer patients.
    Khoo, S.
    Storrer, C. E.
    Harris, K. A.
    Jama, Y. H.
    Dehqanzoda, Z. A.
    Mittendorf, E. A.
    Murray, J. L.
    Shriver, C. D.
    von Hofe, E.
    Ponniah, S.
    Peoples, G. E.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S78 - S78
  • [29] Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Hamilton, Erika
    Blackwell, Kimberly
    Hobeika, Amy C.
    Clay, Timothy M.
    Broadwater, Gloria
    Ren, Xiu-Rong
    Chen, Wei
    Castro, Henry
    Lehmann, Frederic
    Spector, Neil
    Wei, Junping
    Osada, Takuya
    Lyerly, H. Kim
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [30] Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Erika Hamilton
    Kimberly Blackwell
    Amy C Hobeika
    Timothy M Clay
    Gloria Broadwater
    Xiu-Rong Ren
    Wei Chen
    Henry Castro
    Frederic Lehmann
    Neil Spector
    Junping Wei
    Takuya Osada
    H Kim Lyerly
    Journal of Translational Medicine, 10
12345